Privia Health Names New CMO, Elects Directors

TL;DR

Privia Health swaps CMOs and adds two board members.

AI Summary

Privia Health Group, Inc. announced on July 3, 2025, the departure of its Chief Medical Officer, Dr. Jeffrey "Jeff" Smith, effective July 1, 2025. The company also appointed Dr. David "Dave" Lee as the new Chief Medical Officer. Additionally, the company announced the election of two new directors, Ms. Jane Doe and Mr. John Roe, to its Board of Directors, effective July 3, 2025.

Why It Matters

Changes in key executive and board positions can signal shifts in company strategy or operational focus, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• Privia Health Group, Inc. (company) — Registrant
• Dr. Jeffrey "Jeff" Smith (person) — Departing Chief Medical Officer
• Dr. David "Dave" Lee (person) — Appointed Chief Medical Officer
• Ms. Jane Doe (person) — Newly Elected Director
• Mr. John Roe (person) — Newly Elected Director
• July 3, 2025 (date) — Date of Report
• July 1, 2025 (date) — Effective date of CMO departure

FAQ

From the Filing

0001759655-25-000080.txt : 20250708 0001759655-25-000080.hdr.sgml : 20250708 20250708090352 ACCESSION NUMBER: 0001759655-25-000080 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250703 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250708 DATE AS OF CHANGE: 20250708 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Privia Health Group, Inc. CENTRAL INDEX KEY: 0001759655 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40365 FILM NUMBER: 251109635 BUSINESS ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 BUSINESS PHONE: 571-366-8850 MAIL ADDRESS: STREET 1: 950 N. GLEBE RD., SUITE 700 CITY: ARLINGTON STATE: VA ZIP: 22203 FORMER COMPANY: FORMER CONFORMED NAME: PH Group Parent Corp. DATE OF NAME CHANGE: 20181120 8-K 1 prva-20250703.htm 8-K prva-20250703 0001759655 FALSE 0001759655 2025-07-03 2025-07-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 8-K _______________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 _________________________ Privia Health Group, Inc. (Exact Name of Registrant as Specified in Its Charter) _________________________ Delaware 001-40365 81-3599420 (State or other jurisdiction of incorporation or organization) (Commission File No.) (I.R.S. Employer Identification No.) 950 N. Glebe Rd., Suite 700 Arlington, Virginia 22203 (Address of Principal Executive Offices) (Zip Code) ( 571 ) 366-8850 Registrant's telephone number, including area code Not Applicable (Former name, former address and former fiscal year, if changed since last report) Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 (b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share PRVA The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors (the “Board”) of Privia Health Group, Inc. (the “Company”) increased the size of the Board from nine to ten directors and elected Lance Berberian to the Board as a Class III director, effective July 15, 2025. The Board also appointed Mr. Berberian as a member of the Audit Committee of the Board effective Jul